Blog
Log In
Contact us

Tag: data-driven insights

Categories
Editorial

OMNY Health launches ophthalmology-centric real-world data platform in partnership with leading ophthalmology practices focused on improving patient outcomes

In alignment with OMNY Health’s mission to deliver data and insights to accelerate life-changing innovation, these solutions will serve as a catalyst for research and improved outcomes for the 2+ billion individuals impacted by ophthalmic disease

ATLANTA, GA, May 10, 2022 – Today, OMNY Health announced that it has partnered with the nation’s leading community-based ophthalmology practices to launch a first-of-a-kind, real-world data ecosystem focused on driving collaborative research partnerships to advance treatments and improve outcomes in patients with ophthalmic disorders.  Derived from electronic health record data, OMNY solutions provide valuable information on the evolving treatment paradigm for patients with ophthalmic disease, including difficult to obtain insights on the rationale behind treatment decisions, and the impact of social determinants of health on care delivery and outcomes.  De-identified images from retinal scans and other images also are available from ecosystem partners, allowing researchers to view physical changes in condition severity over time.

A diverse set of providers are participating in the ecosystem, from large independent ophthalmology group practices to academic medical centers, integrated delivery networks, specialty hospitals, and regional health systems.  Practices participating in the OMNY ecosystem will leverage OMNY’s platform to opt into clinical trials, prospective observational surveys, and other collaborative research opportunities.

“We are thrilled to welcome our new ophthalmology providers to our network. Over the past year, we have made great strides connecting researchers and providers in the dermatology space and are looking forward to making the same level of impact on ophthalmology,” said Mitesh Rao, MD, CEO, OMNY Health.

“US Eye looks forward to continuing to strengthen our partnership with OMNY Health and find new ways to leverage our data internally,” said Kinga Huse, President, US Eye. “The ability to make more data-driven decisions that improve outcomes and the patient experience will be a valuable asset for our providers and patients.”

“We are excited to have a partner in OMNY that chose to prioritize Ophthalmology. As a data driven organization, we view this partnership as a conduit to leverage our data to gain new insights in providing care for our patients. The added visibility into additional clinical research opportunities will allow our providers to continue their focus on finding new ways to care for and treat our patients in their efforts to preserve sight,” said Amy Goodson-Burke, Chief Revenue Officer, American Vision Partners.

“As a leading administrative services provider for top notch ophthalmology practices, Sight Growth Partners’ primary focus is to listen to our doctors and provide support for them so they can care for their patients in a better way. We are partnering with OMNY Health to do exactly that…exceed our physician’s needs so they can exceed their patient’s needs,” said Jonathan Lujan, CEO, Sight Growth Partners.

“We are thrilled to be a part of the OMNY Health network. It will allow us to better understand our patient populations, obtain more insight into the impact of care patterns on outcomes, and better align clinical trial opportunities with specific patient cohorts,” said David Shoemaker, MD, Founder and CEO, US Eye.

With an uptick in ophthalmology drug research and approvals in the past few years, researchers can utilize this data to expedite clinical trial recruitment and design, understand evolving treatment patterns, assess trends in healthcare resource utilization, understand current gaps in care, conduct comparative effectiveness studies, and partner with ophthalmology practices around joint missions focused on quality improvement and patient outcomes.

Key populations available in the dataset include dry eye (296K patients), dry age-related macular degeneration (AMD) (109K patients), wet AMD (31K patients), and diabetic retinopathy (64K patients). This unique data asset also includes populations with rare eye diseases such as Stargardt Disease and pediatric populations with congenital disease.

Like other OMNY Health specialty-focused databases, the ophthalmology data set also includes information on pharmacy orders, lab results, medical device detail for implants, and detailed provider clinical assessment measures such as best corrected visual acuity and intraocular pressure values. OMNY will be conducting ophthalmology solution demonstrations and presenting results from studies during a variety of events this summer, including ISPOR, DIA, and ICPE.

About OMNY Health

OMNY Health connects patients, providers, and life sciences companies through data and insights to transform healthcare delivery, improve clinical outcomes, and address patients’ unmet needs. Our platform, representing more than 35M patients, enables turnkey research and the ability to convert insights to actions for over 150 disease areas across more than 115,000 providers.

In addition to its ophthalmology data-centered solutions, the OMNY Health ecosystem features a wide range of products that compliantly facilitate collaboration between researchers and providers while maintaining patient privacy. Serving as a key resource and central intermediary, OMNY Health minimizes the effort required by providers and life sciences organizations to achieve these objectives. By aligning the goals of all sides and forging relationships to provide unique, curated data sets and mechanisms to establish compliant partnerships, OMNY Health fuels innovation where patients need it the most.

For more information, go to https://marketing-dev.omnyhealth.com/ or email lifesciences@omnyhealth.com.

MEDIA INQUIRIES:  please contact Stacey Long, stacey@omnyhealth.com

View full press release

Categories
Editorial

Four Ways to Create Knowledge and Value from Healthcare Data Using Analytics and Data Science

Improving outcomes, lowering costs, and increasing quality — in healthcare, these three objectives are known as the “triple aim.” How does investment in healthcare data and analytics help health systems achieve these goals? This question is important. Too often in this field, workers focus on the “how” while ignoring the “why.” It can be relatively easy for data and analytics teams to build an app or a notebook that “looks cool” or grabs some attention on social media by demonstrating a new functionality; however, the challenge is applying that work towards the healthcare triple aim.  

So how exactly can data and analytics teams contribute towards the healthcare triple aim? At a high level, here are four ways: 

Invest in open-source tools

Sometimes, analytics teams rely on certain tools or software with less favorable properties than others. Some tools are not suited for big amounts of healthcare data and may have file size limitations; some rely on a learning curve that includes “learning where to mouse-click”; some may require expensive licenses. Clinical and healthcare analytics experiences indicate that the future lies in tools that rely/focus on the following: (1) knowledge of coding; (2) open-source, community-based development; and/or (3) repeatable, reproducible, and programmatic processes.   

Embrace new analytics technologies

The field of healthcare can be resistant to change. For example, when automated blood pressure machines were introduced to hospital wards, there was some hesitancy and disbelief that automated cuffs could accurately take blood pressure. Today, these cuffs are a mainstay in hospitals and free up precious time of nurses to achieve other care needs. Analytics technologies that face similar skepticism include specific types of artificial intelligence, including machine learning, deep learning, and natural language processing. 

Align with healthcare systems towards product development

To ensure that time consuming product development will benefit health systems, it is important to involve health systems at multiple points throughout the process. For analytics applications, this involvement often involves using a modern agile approach that focuses on rapid sprints and repeated healthcare system touchpoints, releases, iterations, and improvements of a product, rather than a traditional waterfall model that focuses on a single, lengthy iteration of the software development lifecycle. 

Take advantage of new payment models and government incentives

As the United States switches from a fee-for-service payment system towards a value-based care system that rewards quality over quantity of healthcare services, the government is offering many financial incentives for health systems to improve outcomes, quality of care, and satisfaction. An overview of such programs at the federal level can be found here: https://www.cms.gov/Medicare/Quality-Initiatives-Patient-Assessment-Instruments/Value-Based-Programs/Value-Based-Programs .  

Generating useful insights from healthcare data through analytics is not a one-day project — it can take weeks to several years for relevant teams to achieve desired goals, depending on the bottom-line impact amount and the project. These four high-level ideas described above can serve as a starting point to extract value from healthcare data. Looking forward to bringing you more webinars and blog posts throughout the year that will focus on specific, lower-level techniques and tools for creating knowledge and value from healthcare data. 

About the Author:
Vikas Kumar, MD, MS is a Senior Data Scientist at OMNY Health where he works on data science projects that focus on real-world clinical evidence, machine learning, and natural language processing. In his spare time, he has also authored a book on healthcare analytics, contributed to two online healthcare informatics courses, and currently serves as a teaching assistant for a graduate level data science course at the Georgia Institute of Technology. He holds a Doctor of Medicine degree from the University of Pittsburgh and a Master of Science in Computational Science and Engineering degree from the Georgia Institute of Technology. s across the country in order to help guide the development of innovative solutions that can sustainably impact patient care.

Categories
News

Sensyne Health and OMNY Health Sign Teaming Agreement to Support Breakthrough Research Through the Power of Real World Data and AI

Sensyne and OMNY will collaborate to develop new proposals to life sciences companies and healthcare providers to use real world data and advanced analytical tools to improve patient outcomes and accelerate the development of new medicines

The Teaming Agreement allows OMNY to engage Sensyne’s data analytics tools and consulting services and provides Sensyne with the potential to access OMNY Health’s 22 million de-identified patient records

Dover, DE and Atlanta, GA. Oxford, U.K. October 13, 2021: Sensyne Health plc (LSE: SENS) (“Sensyne”), the ethical Clinical AI company, and OMNY Health (“OMNY”), a leading US-based real world data company, today announced a strategic teaming relationship.

The arrangement establishes a nimble framework under which Sensyne can subscribe to data offerings via the OMNY Health Platform, which features more than 22 million de-identified patient records across broad therapeutic areas in support of Sensyne’s data analytics work for life science companies. In addition, Sensyne and OMNY have agreed to work together on commercial projects for life science clients to advance and accelerate ethical medical research.  By bringing biopharma clients a joint offering with OMNY real-world data and Sensyne machine learning expertise, both companies—and their health system partners—will have more opportunities to support important life sciences research.

The OMNY data network complements Sensyne’s existing global medical research dataset of 22.1 million patients, ethically sourced through strategic partnerships with US health systems and the UK’s National Health Service (NHS) trusts. With representation from  over 50,000 providers across 40 states, the OMNY Health Platform also offers control, security, and data governance to maximize the utility of information while maintaining compliance with US regulations.  Sensyne will now have a new avenue to access data from OMNY’s catalog of over 22 million unique patient records, significantly enhancing the scale of real world data on which Sensyne can apply its advanced machine learning and bringing the possible combined total of de-identified patient data available for collaborative research to over 44m patients.  

Derek Baird, President, North America, Sensyne Health said:

“This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries. The team at OMNY, like us, appreciate the complexity of working with longitudinal clinical records, and the trust that health systems place in our companies to analyse de-identified patient data in an ethical, secure, and responsible way.  We share common philosophies and missions, and complementary approaches in responsibly using real-world data to accelerate life science research for clients. This is an exciting alliance, and we are thrilled to be working together.”

Mitesh Rao, MD, CEO, OMNY Health said:

“OMNY Health embraces the opportunity to work with Sensyne Health’s world-class machine learning team and data science professionals, and is thrilled for Sensyne to join the platform.  We aim to revolutionize the healthcare ecosystem through our equality-driven data network while unlocking transformative real world data partnerships across the life sciences industry. This collaboration with Sensyne Health creates even greater possibilities to apply emerging technologies to the unparalleled data we’ve assembled, enabling both companies to ethically innovate on behalf of our respective partners, and most importantly, to create better outcomes for patients.”
Sensyne is working with life science partners on different types of research projects across multiple disease areas. The actionable insights from OMNY’s longitudinal patient data sets will help them with synthetic control arms, patient stratification, patient identification and selection, plus important late-phase clinical trial design, commercialisation, and health economic pricing decisions.

For more information email: lifesciences@omnyhealth.com.

Categories
News

OMNY Health Launches Massive Integrated Dermatology Data Repository and Research Network to Advance Life-Changing Innovations for Patients Suffering from Skin-Related Conditions

ATLANTA, June 23, 2021 /PRNewswire/ — OMNY Health (OMNY Inc.) is pleased to announce it has partnered with the nation’s leading community-based dermatology practices to create a first-of-a-kind integrated, normalized, de-identified electronic health record (EHR) data repository for dermatological research.

The assembled longitudinal data represents care delivered over the past five years by over 1,000 dermatologic providers in more than 30 states, across more than 7.5 million unique patients. OMNY Health works with providers to integrate and standardize their siloed disparate EHR data, enabling the delivery of de-identified data into research-ready subscriptions for Life Sciences organizations, while also delivering insights based on the normalized data back to the data contributors.

At the core of the OMNY Health platform is de-identified, normalized EHR data, further enhanced with tokens that support linkages to data derived from administrative claims, registries and other data resources, while maintaining patient anonymity. OMNY Health leverages natural language processing (NLP) technology to analyze unstructured data to derive insights often buried in clinician notes, such as adverse drug events, social determinants of health, and reasons for therapy changes.

“We are excited to partner with these forward-thinking dermatology providers to launch OMNY Health’s first suite of specialty databases. As the number of specialty treatment options expands, OMNY Health provides an ideal platform for delivering scalable data solutions to life sciences companies needing to understand the care delivered by the diverse mix of providers treating patients along their care journey. Data available on the platform provides the information needed to better understand the patient and provider landscape, design and identify eligible patients for trials, monitor the impact of launch of new therapies in the real-world setting, and evaluate safety and effectiveness of those therapies”, said Dr. Mitesh Rao, CEO at OMNY Health.

Investment in dermatology has experienced double-digit growth over the past several years and is expected to continue to grow, particularly for the conditions falling at the intersection of inflammatory and autoimmune skin disorders, such as alopecia areata, psoriasis, and atopic dermatitis. “We can now address the retrospective and prospective data and analytic needs of life sciences organizations working on treatments for some of the rarest dermatologic conditions, such as epidermolysis bullosa and generalized pustular psoriasis, to common conditions such as acne, and everything in between,” said Stacey Long, Chief Strategy Officer, who oversees OMNY Health’s product and data science teams.

“Advanced Dermatology and Cosmetic Surgery, the nation’s premier dermatology practice, values our partnership with OMNY. As we actively explore cutting edge therapeutics and leverage our robust data set to find ways to best serve our patients and the dermatology community, a collaboration with an advanced partner, like OMNY is crucial to our long-term success.” Allison W. Lynch, Chief Operating Officer, Clinical Research

“We are excited to partner with OMNY Health in looking at real world data. It’s an invaluable resource that creates improved patient outcomes, quality metrics, cost efficiencies, and tools for evaluating best practice opportunities. It also allows for prospective research to evaluate new ideas, therapies, and measurement tools that can assist in making better decisions for patients, physicians, payers, and the industry,” said Dr. Mark Jackson, Clinical Professor of Dermatology, University of Louisville and Director of Medical/Clinical Research, Forefront Dermatology.

Dr. Jackson will join Lawrence Rasouliyan, OMNY Health’s Head of Biostatistics and Data Science, on June 24, for a webinar discussion on the vital role of physicians in supporting real-world evidence generation in dermatology and the transformative opportunity for patients, providers, and life sciences organizations. Register at Events & Webinars

About OMNY Health

OMNY Health connects patients, providers, and life sciences companies through data and insights to transform healthcare delivery, improve clinical outcomes, and address patient’s unmet needs. For more information, go to https://marketing-dev.omnyhealth.com/ or email: lifesciences@omnyhealth.com.

View full press release